# A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors

> **NCT07105215** · PHASE1,PHASE2 · RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 312 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** RC278

## Key facts

- **NCT ID:** NCT07105215
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-11
- **Primary completion:** 2027-12-31
- **Final completion:** 2030-05-31
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07105215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07105215, "A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT07105215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*